Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced

Cencora, Inc.

Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.
Entered $1.5B term loan facility ($500M Tranche One, $1.0B Tranche Two) to fund acquisition.
Entered $3.0B 364-day term loan facility to pay consideration and fees for acquisition.
Existing $4.5B bridge financing automatically reduced to zero upon new facilities.
Interest margins range from 75-125 bps over SOFR; leverage covenant max 4.00x with potential increase to 4.50x.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.